as on October 23, 2025 at 1:29 am IST
Day's Low
Day's High
-0.19%
Downside
8.42%
Upside
52 Week's Low
52 Week's High
33.61%
Downside
109.36%
Upside
Check Denali Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$2.3B
EPS (TTM)
-3.0268
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-8.32
Industry PE ratio
8.355964912280701
PEG Ratio
0EBITDA
-529.4M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
0.00%
Track how Denali Therapeutics Inc P/E has moved over time to understand its valuation trends.
Denali Therapeutics Inc in the last 5 years
Lowest (-26.15x)
September 30, 2023
Today (-8.32x)
October 23, 2025
Industry (8.36x)
October 23, 2025
Highest (-5.03x)
June 30, 2025
Today’s Price to Earnings Ratio: -8.32x
Compare market cap, revenue, PE, and other key metrics of Denali Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $2.3B | -61.23% | -8.32 | 0.00% | |
BUY | $63.1B | 252.62% | -505.15 | -12.96% | |
NA | $35.3B | NA | NA | -3.89% | |
BUY | $109.3B | 101.55% | 30.36 | 31.86% | |
BUY | $61.3B | 0.85% | 14.6 | 31.37% |
The Denali Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Denali Therapeutics Inc investment value today
Current value as on today
₹65,600
Returns
Returns from Denali Therapeutics Inc Stock
Dollar Returns*
₹4,557 (+4.56%)
Based on 23 analysts
86.96%
Buy
13.04%
Hold
0.00%
Sell
Based on 23 analysts, 86.96% of analysts recommend a 'BUY' rating for Denali Therapeutics Inc. Average target price of $31.6
Get share price movements and forecasts by analysts on Denali Therapeutics Inc.
What analysts predicted
49.62%UPSIDE
Target Price
$31.6
Current Price
$15.92
Analyzed by
23 Analysts
Target
$31.60
Denali Therapeutics Inc target price $31.6, a slight upside of 49.62% compared to current price of $15.92. According to 23 analysts rating.
Search interest for Denali Therapeutics Inc Stock has increased by 705% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:705% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 14 October
Tue, 05:53 PM
-FDA extends review timeline for Denali's tividenofusp alfa from Jan. 5, 2026, to April 5, 2026, due to updated information submission.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 2 quarters, -132.97M → -124.11M (in $), with an average increase of 7.1% per quarter
Price Rise
In the last 1 month, DNLI stock has moved up by 22.2%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 133.8% return, outperforming this stock by 177.5%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.7% return, outperforming this stock by 96.5%
Revenue Fall
Revenue is down for the last 3 quarters, 294.12M → -305.04M (in $), with an average decrease of 12137.8% per quarter
Organisation | Denali Therapeutics Inc |
Headquarters | 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Industry | Health Technology |
CEO | Dr. Ryan J. Watts Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director |
Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Secretary |
Dr. Carole Ho M.D. | Chief Medical Officer & Head of Development |
Dr. Dana Andersen | Chief Technical and Manufacturing Officer |
Mr. Joe Lewcock Ph.D. | Chief Scientific Officer |
Mr. Chris Walsh J.D. | General Counsel |
Ms. Cindy Dunkle | Chief People Officer |
Ms. Katie Peng | Chief Commercial Officer |
Denali Therapeutics Inc share price today is $15.92 as on at the close of the market. Denali Therapeutics Inc share today touched a day high of $17.26 and a low of $15.95.
Denali Therapeutics Inc share touched a 52 week high of $33.33 on and a 52 week low of $10.57 on . Denali Therapeutics Inc stock price today i.e. is closed at $15.92,which is 52.24% down from its 52 week high and 50.61% up from its 52 week low.
Denali Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Denali Therapeutics Inc (DNLI) shares with as little as ₹87.755 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹877.55 in Denali Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Denali Therapeutics Inc share’s latest price of $15.92 as on October 23, 2025 at 1:29 am IST, you will get 0.6281 shares of Denali Therapeutics Inc. Learn more about
fractional shares .
Denali Therapeutics Inc stock has given -61.23% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?